A. Hill

发表

Highly Active Antiretroviral Therapy (HAART) Retreatment in Patients on CD4-Guided Therapy Achieved Similar Virologic Suppression Compared With Patients on Continuous HAART: The HIV Netherlands Australia Thailand Research Collaboration 001.4 Study

B. Hirschel, J. Ananworanich, K. Ruxrungtham, 2005, Journal of acquired immune deficiency syndromes.

Pharmacokinetics of Efavirenz 400 mg Once Daily Coadministered With Isoniazid and Rifampicin in Human Immunodeficiency Virus–Infected Individuals

A. Owen, M. Boffito, M. Mcclure, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxis

Lee M. Tatham, Christopher A. W. David, S. Khoo, 2020, medRxiv.

Dose prediction for repurposing nitazoxanide in SARS‐CoV‐2 treatment or chemoprophylaxis

Lee M. Tatham, Christopher A. W. David, S. Khoo, 2020, British journal of clinical pharmacology.

Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets

A. Haycox, S. Simoens, B. Wettermark, 2018, Front. Public Health.

High sustained virological response rates using imported generic direct acting antiviral treatment for hepatitis C

A. Hill, Giten Khwairakpam, R. Korologou-Linden, 2017, Journal of virus eradication.

Safety and on-treatment efficacy of telaprevir: the early access programme for patients with advanced hepatitis C

M. Colombo, H. Wedemeyer, A. Streinu-Cercel, 2013, Gut.

Importation of generic hepatitis C therapies: bridging the gap between price and access in high-income countries

R. Day, G. Dore, W. Lipworth, 2017, The Lancet.

Importation of generic hepatitis C therapies: Bridging the price - access gap in high-income countries

R. Day, G. Dore, W. Lipworth, 2016 .

Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus

N. Ford, G. Cooke, S. Khoo, 2015, Hepatology.

Research letter: is monitoring for CD4 counts still needed for the management of patients with long-term HIV RNA suppression?

C. Stephan, N. Xi, A. Hill, 2012, Journal of acquired immune deficiency syndromes.

No Difference in the Rate of Change in Telomere Length or Telomerase Activity in HIV-Infected Patients after Three Years of Darunavir/Ritonavir with and without Nucleoside Analogues in the MONET Trial

S. Lewin, J. Arribas, A. Hill, 2014, PloS one.

Pharmacokinetics of Lamivudine and Lamivudine-Triphosphate after Administration of 300 Milligrams and 150 Milligrams Once Daily to Healthy Volunteers: Results of the ENCORE 2 Study

S. Khoo, S. Emery, R. Puls, 2011, Antimicrobial Agents and Chemotherapy.

Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients

K. Ruxrungtham, D. Cooper, R. Autar, 2007, AIDS.

Time to HIV-1 RNA suppression below 5 copies/ml during first-line protease inhibitor-based antiretroviral treatment - any impact of residual viremia on treatment success?

D. Ripamonti, A. Hill, C. Moecklinghoff, 2013, AIDS reviews.

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

A. Horban, N. Clumeck, G. Fätkenheuer, 2010, AIDS.

Relative antiviral efficacy of ritonavir‐boosted darunavir and ritonavir‐boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials

A. Hill, G. Moyle, Andrew Hill, 2007, HIV medicine.

Interpretation of resistance data from randomized trials of first-line antiretroviral treatment.

B. Clotet, Ravindra K. Gupta, A. Hill, 2012, AIDS reviews.

Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain

A. Hill, J. Pasquau, C. Moecklinghoff, 2012, Applied Health Economics and Health Policy.

Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results

B. Gazzard, A. Castagna, A. Hill, 2011, AIDS.

96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline.

A. Rieger, N. Clumeck, J. Arribas, 2011, The Journal of antimicrobial chemotherapy.

A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population

B. Gazzard, D. Podzamczer, H. Stellbrink, 2011, AIDS.

Is There a Higher Risk of CNS Adverse Events for PI Monotherapy Versus Triple Therapy? A Review of Results From Randomized Clinical Trials

W. Powderly, A. Hill, C. Moecklinghoff, 2014, HIV clinical trials.

Neurocognitive disorders during antiretroviral treatment, despite full HIV RNA suppression

J. Arribas, A. Hill, 2010 .

A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial

B. Gazzard, Z. Fox, M. Youle, 2005, Antiviral therapy.

Analysis of Drug Resistance during HIV RNA Viraemia in the Monet Trial of Darunavir/Ritonavir Monotherapy

J. Arribas, A. Hill, F. Pulido, 2011, Antiviral therapy.

Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial.

J. Arribas, N. Xi, A. Hill, 2012, The Journal of antimicrobial chemotherapy.

DolPHIN-1: Randomised controlled trial of dolutegravir (DTG)- versus efavirenz (EFV)-based therapy in mothers initiating antiretroviral treatment in late pregnancy

L. Myer, S. Khoo, C. Orrell, 2018 .

The PROTEA trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV-1 RNA below 50 copies/mL

A. Antinori, A. Horban, J. Fehr, 2014, Journal of the International AIDS Society.

d4T: keep it or abandon it?

A. Hill, 2010 .

A Prospective Study of Efficacy and Safety of Once-Daily Saquinavir/Ritonavir plus Two Nucleoside Reverse Transcriptase Inhibitors in Treatment-Naive Thai Patients

B. Hirschel, J. Ananworanich, R. Nuesch, 2005, Antiviral therapy.

Minimum Costs for Producing Hepatitis C Direct-Acting Antivirals for Use in Large-Scale Treatment Access Programs in Developing Countries

N. Ford, S. Khoo, Bryony Simmons, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Influence of atazanavir 200 mg on the intracellular and plasma pharmacokinetics of saquinavir and ritonavir 1600/100 mg administered once daily in HIV-infected patients.

B. Gazzard, S. Khoo, J. Ford, 2006, The Journal of antimicrobial chemotherapy.

Intracellular and Plasma Pharmacokinetics of Saquinavir-Ritonavir, Administered at 1,600/100 Milligrams Once Daily in Human Immunodeficiency Virus-Infected Patients

B. Gazzard, S. Khoo, J. Ford, 2004, Antimicrobial Agents and Chemotherapy.

Changes in hematologic parameters and efficacy of thymidine analogue-based, highly active antiretroviral therapy: a meta-analysis of six prospective, randomized, comparative studies.

M. Law, J. Amin, G. Moyle, 2004, Clinical therapeutics.

Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics

Lee M. Tatham, Christopher A. W. David, S. Khoo, 2020, Clinical pharmacology and therapeutics.

Pharmacokinetics, Efficacy, and Safety of Darunavir/Ritonavir 800/100 mg Once-Daily in Treatment-Naïve and -Experienced Patients

M. Boffito, A. Hill, D. Miralles, 2008, HIV clinical trials.

Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.

B. Gazzard, M. Boffito, D. Back, 2006, AIDS research and human retroviruses.

Changes in Patient-reported Neuropsychiatric Outcomes during the SENSE Trial: First-line Treatment with Two Nucleoside Analogues plus Etravirine or Efavirenz

C. Katlama, H. Furrer, P. Morlat, 2012 .

Pharmacokinetic and tolerability profile of twice‐daily saquinavir hard gelatin capsules and saquinavir soft gelatin capsules boosted with ritonavir in healthy volunteers

M. Kurowski, A. Hill, A. Sawyer, 2003, HIV medicine.

Pharmacokinetics of once-daily saquinavir hard-gelatin capsules and saquinavir soft-gelatin capsules boosted with ritonavir in HIV-1-infected subjects.

K. Ruxrungtham, D. Cooper, P. Phanuphak, 2003, Journal of acquired immune deficiency syndromes.

The effect of ritonavir on saquinavir plasma concentration is independent of ritonavir dosage: combined analysis of pharmacokinetic data from 97 subjects

A. Hill, N. Buss, JM Kilby, 2002, HIV medicine.

Should the dose of tenofovir be reduced to 200–250 mg/day, when combined with protease inhibitors?

S. Khoo, M. Boffito, D. Back, 2014, Journal of the International AIDS Society.

Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily.

B. Hirschel, K. Ruxrungtham, D. Cooper, 2004, The Journal of antimicrobial chemotherapy.

Boosted saquinavir hard gel formulation exposure in HIV-infected subjects: ritonavir 100 mg once daily versus twice daily.

B. Gazzard, M. Boffito, D. Back, 2005, The Journal of antimicrobial chemotherapy.

Pharmacokinetics of saquinavir hard gel/ritonavir (1000/100 mg twice daily) when administered with tenofovir diproxil fumarate in HIV-1-infected subjects.

B. Gazzard, G. di Perri, M. Boffito, 2005, British journal of clinical pharmacology.

Steady-State Pharmacokinetics of Saquinavir Hard-Gel/Ritonavir/Fosamprenavir in HIV-1–Infected Patients

B. Gazzard, M. Boffito, D. Back, 2004, Journal of acquired immune deficiency syndromes.

Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen

B. Gazzard, M. Kurowski, M. Boffito, 2004, AIDS.

Pharmacokinetics of Once-Daily Saquinavir/Ritonavir in HIV-Infected Subjects: Comparison with the Standard Twice-Daily Regimen

B. Gazzard, M. Boffito, D. Back, 2003, Antiviral therapy.

How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials

Andrew Hill, M. Boffito, A. Hill, 2009, AIDS.

Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial.

Z. Fox, P. Vernazza, M. Youle, 2003, The Journal of infectious diseases.

A Randomized Trial to Evaluate Continuation versus Discontinuation of Lamivudine in Individuals Failing A Lamivudine-Containing Regimen: The Colate Trial

Z. Fox, C. Katlama, A. Phillips, 2005, Antiviral therapy.

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C

Bryony Simmons, J. Fortunak, A. Hill, 2016, Journal of virus eradication.

Efficacy of 400 mg efavirenz versus standard 600 mg dose in HIV-infected, antiretroviral-naive adults (ENCORE1): a randomised, double-blind, placebo-controlled, non-inferiority trial

B. Gazzard, D. Cooper, P. Phanuphak, 2014, The Lancet.

Pharmacokinetics and 24-Week Efficacy/Safety of Dual Boosted Saquinavir/Lopinavir/Ritonavir in Nucleoside-Pretreated Children

J. Ananworanich, K. Ruxrungtham, U. Siangphoe, 2005, The Pediatric infectious disease journal.

Pharmacokinetics of low-dose protease inhibitors and efavirenz in low- and middle-income countries

K. Ruxrungtham, A. Hill, D. Burger, 2010, Current opinion in HIV and AIDS.

Pharmacokinetics and Pharmacodynamics of Etravirine 400 mg Once Daily in Treatment-Naïve Patients

M. Kurowski, M. Bickel, G. di Perri, 2013, HIV clinical trials.

Systematic Review to Determine the Prevalence of Transmitted Drug Resistance Mutations to Rilpivirine in HIV-Infected Treatment-Naive Persons

V. Calvez, J. Vingerhoets, A. Hill, 2016, Antiviral therapy.

The Steady-State Pharmacokinetics of Nelfinavir in Combination with Tenofovir in HIV-Infected Patients

M. Kurowski, S. Esser, A. Hill, 2005, Antiviral therapy.

Pharmacokinetics of plasma lopinavir/ritonavir following the administration of 400/100 mg, 200/150 mg and 200/50 mg twice daily in HIV-negative volunteers.

B. Gazzard, S. Khoo, S. Emery, 2011, The Journal of antimicrobial chemotherapy.

Synergistic Inhibition of Protease-Inhibitor-Resistant HIV type 1 by Saquinavir in Combination with Atazanavir or Lopinavir

L. Essioux, F. Clavel, A. Hill, 2006, Antiviral therapy.

Pharmacokinetics of and Short-Term Virologic Response to Low-Dose 400-Milligram Once-Daily Raltegravir Maintenance Therapy

J. Ananworanich, K. Ruxrungtham, S. Kerr, 2012, Antimicrobial Agents and Chemotherapy.

Modelling-Based Prediction of Clinical Benefits from Etravirine in the TMC125-C223 Trial

M. Peeters, A. Hill, J. Nadler, 2007, HIV clinical trials.

Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme.

M. Loutfy, S. De Wit, E. Ribera, 2009, The Journal of antimicrobial chemotherapy.

Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.

A. Geretti, J. Vingerhoets, A. Hill, 2014, The Journal of antimicrobial chemotherapy.

Can we stop CD4+ testing in patients with HIV-1 RNA suppression on antiretroviral treatment?

M. Nelson, A. Hill, P. Girard, 2013, AIDS.

Impact of hepatitis C co-infection on response to antiretroviral treatment.

A. Hill, F. Pulido, C. Moecklinghoff, 2012, AIDS reviews.

Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.

M. Kurowski, A. Hill, K. Arastéh, 2007, The Journal of antimicrobial chemotherapy.

Pricing of oral generic cancer medicines in 25 European countries; findings and implications

Steven Simoens, Brian Godman, Guenka Petrova, 2019, Generics and Biosimilars Initiative Journal.

Highly Active Antiretroviral Therapy (HAART) Retreatment in Patients on CD4-Guided Therapy Achieved Similar Virologic Suppression Compared With Patients on Continuous HAART: The HIV Netherlands Australia Thailand Research Collaboration 001.4 Study

B. Hirschel, J. Ananworanich, K. Ruxrungtham, 2005, Journal of Acquired Immune Deficiency Syndromes.

InterPrEP. Internet-based pre-exposure prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of outcomes in 641 patients

M. Boffito, A. Hill, N. Nwokolo, 2017, Journal of virus eradication.

InterPrEP: Internet-based pre-exposure prophylaxis with generic tenofovir DF and emtricitabine in London: an analysis of outcomes in 641 patients. Journal of Virus Eradication , 3 (4), http://viruseradication.com/journal-details/InterPrEP._Internet-based_pre-exposure_prophylaxis_with_generic_tenofov

M. Boffito, A. Hill, N. Nwokolo, 2017 .

Improvement in vitamin D deficiency following antiretroviral regime change: Results from the MONET trial.

J. Fox, J. Arribas, B. Peters, 2011, AIDS research and human retroviruses.

Dynamics of cellular HIV-1 DNA levels over 144 weeks of darunavir/ritonavir monotherapy versus triple therapy in the MONET trial.

J. Arribas, A. Geretti, A. Hill, 2012, HIV clinical trials.

Sustained virological response with telaprevir in 1,078 patients with advanced hepatitis C: the international telaprevir access program.

H. Wedemeyer, A. Streinu-Cercel, Christophe Moreno, 2014, Journal of hepatology.

Z. Fox, C. Katlama, A. Phillips, 2006 .

Target prices for mass production of tyrosine kinase inhibitors for global cancer treatment

Mark Bower, Andrew Hill, H. Shoman, 2016, BMJ Open.

Estimated generic prices of cancer medicines deemed cost-ineffective in England: a cost estimation analysis

Andrew Hill, A. Hill, Dzintars Gotham, 2017, BMJ Open.

Predictors of long-term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial

J. Arribas, A. Hill, F. Pulido, 2013, International journal of STD & AIDS.

Performance of the Abbott RealTime HIV-1 assay versus the roche amplicor HIV-1 MonitorTM Test, v1.5, UltraSensitive assay for samples with low plasma HIV-1 RNA copy numbers.

C. Stephan, A. Hill, C. Moecklinghoff, 2014, The Journal of antimicrobial chemotherapy.

Predictors of HIV RNA Suppression on Darunavir/Ritonavir Monotherapy or Triple Therapy in the MONET and PROTEA Trials

D. Ripamonti, A. Hill, R. Demasi, 2015 .

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.

J. Ananworanich, R. Nuesch, K. Ruxrungtham, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Dynamics of Cellular HIV-1 DNA Levels Over 144 Weeks of Darunavir/Ritonavir Monotherapy Versus Triple Therapy in the MONET Trial

J. Arribas, A. Geretti, A. Hill, 2013 .

Estimated generic prices for novel treatments for drug-resistant tuberculosis

Frederick E. Nytko, G. Cooke, S. Khoo, 2017, The Journal of antimicrobial chemotherapy.

Etravirine as a Switching Option for Patients with HIV RNA Suppression: A Review of Recent Trials

M. Nelson, A. Hill, C. Moecklinghoff, 2014, AIDS research and treatment.

Impact of NRTI backbone on renal, bone and cardiovascular markers in HIV-infected individuals receiving a boosted protease inhibitor

M. Boffito, M. Nelson, G. Moyle, 2014, Journal of the International AIDS Society.

Etravirine limits the emergence of darunavir and other protease inhibitor resistance-associated mutations in the DUET trials

M. Peeters, H. Azijn, J. Vingerhoets, 2010, AIDS.

Prevalence of HIV Protease Mutations on Failure of Nelfinavir-Containing HAART: A Retrospective Analysis of Four Clinical Studies and Two Observational Cohorts

Lidia Ruiz, Bonaventura Clotet, Eugènia Negredo, 2002, HIV clinical trials.

NINETY-SIX % SVR RATES USING IMPORTED GENERIC DAAs FOR PATIENTS WITH HEPATITIS C

A. Pozniak, A. Hill, Giten Khwairakpam, 2017 .

Effects of switching to protease inhibitor monotherapy on nucleoside analogue-related adverse events.

N. Clumeck, A. Hill, C. Moecklinghoff, 2014, AIDS reviews.

Efficacy, safety and CNS effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine in a randomized controlled trial.

A. Winston, H. Teppler, Valerie Teal, 2021, AIDS.

No evidence for evolution of protease inhibitor resistance from standard genotyping, after three years of treatment with darunavir/ritonavir, with or without nucleoside analogues.

J. Arribas, A. Hill, F. Pulido, 2012, AIDS research and human retroviruses.

InterPrEP. Internet-based pre-exposure prophylaxis with generic tenofovir DF/emtricitabine in London: an analysis of outcomes in 641 patients

M. Boffito, A. Hill, N. Nwokolo, 2017, Journal of virus eradication.

96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline.

A. Rieger, N. Clumeck, J. Arribas, 2011, The Journal of antimicrobial chemotherapy.

Development of HIV with drug resistance after CD4 cell count-guided structured treatment interruptions in patients treated with highly active antiretroviral therapy after dual-nucleoside analogue treatment.

J. Ananworanich, R. Nuesch, K. Ruxrungtham, 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.